Get started
Author

Tim M. Monahan

Observed name: Tim Monahan
Observed institution: Fred Hutch Cancer Center
ORCID: 0009-0007-3006-2746
Observed ORCID: 0009-0007-3006-2746
OpenAlex ID: A5138815544
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia
2019 · Janghee Woo, Dae Ro Choi, et al. · Haematologica · 34
PDF
Discovery of U2AF1 neoantigens in myeloid neoplasms
2023 · Melinda Ann Biernacki, Jessica Lok, et al. · Journal for ImmunoTherapy of Cancer · 23
PDF
Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis
2020 · H. Joachim Deeg, Rachel B. Salit, et al. · Transplantation and Cellular Therapy · 20
SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2025 · Melinda A. Biernacki, Jessica Lok, et al. · Cancer Immunology Research · 6
Figure S5 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Figure S4 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Table S1 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Figure S3 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Figure S2 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Supplementary Data File S1 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Figure S1 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Data from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Figure S6 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Table S2 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
Figure S7 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
2026 · Melinda A. Biernacki, Jessica Lok, et al.
CAR-T Access Barriers in Washington: Experience from a Single Primary Referral Center Prior to Implementing Program Capacity Expansion
2026 · Melinda Ann Biernacki, Dwight C Macero, et al. · Transplantation and Cellular Therapy
The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication
2025 · Jieya Wu, Guangrong Qin, et al. · Blood
Pretransplant Chromosome Genomic Array Testing Improves Prognostication for Myelofibrosis Patients Undergoing Transplantation
2024 · Xiaoyu Qu, Emily Stevens, et al. · Transplantation and Cellular Therapy
66. Prognostic impact of genomic testing results in patients undergoing transplantation for myelofibrosis
2024 · Xiaoyu Qu, Emily Stevens, et al. · Cancer Genetics
Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study
2023 · Helen Ajufo, Andriy Derkach, et al. · Blood
PDF
Works count: 20
Citation count: 83
H-index: 4
I10-index: 3
Year
Topic
Type